Open Access 2023 Webinar: Critical Factors to Assess When Sourcing Viral or Non-Viral Engineering CMOs for Gene Modified Therapies

Recorded On: 12/06/2023

Register
- Non-member - Free!
- Member - Free!
- Advanced Practice Professional Member - Free!
- Community Administrator - Free!
- Complimentary Member - Free!
- Emeritus Member - Free!
- Industry Community - Free!
- Industry Community Sub Account - Free!
- Laboratory Member - Free!
- Laboratory Technologist Sub Account - Free!
- Laboratory Regular Member Sub Account - Free!
- Laboratory Resident and Fellow Sub Account - Free!
- Non-member Advanced Practice Professional - Free!
- Non-member Regular - Free!
- Non-member Resident or Fellow - Free!
- Non-member Technologist - Free!
- Regular Member - Free!
- Resident or Fellow Member - Free!
- Student Member - Free!
- Technologist Member - Free!
Continue

Presented by the ISCT Business Development & Finance Committee

December 6, 2023

Webinar Description:

This webinar will provide insights on the pros and cons of different methods of gene transfer and how to pressure test potential challenges with each method in the context of therapeutics development. A panel discussion from experts in viral and non-viral vector manufacturing will explore the most typical questions that are surfaced during due diligence and vendor qualification for AAV, lentivirus or lipid nanoparticles. Additionally, we will look to explore the questions that are not asked but should be asked by clients when engaging with vector CDMOs or for investors exploring opportunities in this field.

Key Learning Objectives:
• Gain insights on what questions to raise when sourcing a gene engineering partner be it (viral or non-viral) methods
• Understand the potential bumps in the road that can impact time to clinic for the Therapeutic Company
• What to expect in variability of cost impact to over COGS of a cell therapy